Protagonist Therapeutics Q2 EPS $(0.68) Misses $(0.65) Estimate
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics reported Q2 losses of $(0.68) per share, missing the analyst consensus estimate of $(0.65) by 4.62%. However, this is a 19.05% increase over losses of $(0.84) per share from the same period last year.
August 04, 2023 | 2:36 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Protagonist Therapeutics' Q2 earnings per share of $(0.68) missed the consensus estimate, but improved 19.05% YoY.
Protagonist Therapeutics reported a larger loss than expected, which could negatively impact the stock price. However, the YoY improvement might mitigate some of the negative impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100